Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olafertinib (CK-101) in Advanced Solid Tumors and EGFR-Mutant NSCLC
NCT02926768Phase 1Completed
- Sponsor
- Checkpoint Therapeutics, Inc.
- Start
- Sep 2016
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of olafertinib in non-small cell lung cancer (NSCLC) and solid tumor (advanced stage), sponsored by Checkpoint Therapeutics, Inc. Primary endpoints: Incidence of dose-limiting toxicities and Objective Response Rate. Started Sep 2016; status: completed.
02
Drugs
olafertinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02926768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02926768.